BCRX • NASDAQ
Follow
BioCryst Pharmaceuticals, Inc.
Previous close
$10.58
Day range
$10.33 - $10.92
Year range
$7.61 - $19.99
Market cap
2.01B USD
Avg Volume
3.29M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Financial performance
Revenue
Net income
| (USD) | Mar 2022info | Y/Y change |
|---|---|---|
Revenue | 49.92M | 161.94% |
Operating expense | 34.28M | 55.02% |
Net income | -74.20M | -15.42% |
Earnings per share | -0.40 | -11.11% |
EBITDA | -49.64M | 3.04% |
Effective tax rate | -0.38% | — |
Balance Sheet
Financial performance
Total assets
Total liabilities
| (USD) | Mar 2022info | Y/Y change |
|---|---|---|
Cash and short-term investments | 443.47M | 84.50% |
Total assets | 527.72M | 85.54% |
Total liabilities | 691.94M | 92.51% |
Total equity | -164.22M | — |
Shares outstanding | 185.58M | — |
Price to book | -12.02 | — |
Return on assets | -22.38% | — |
Return on capital | -26.71% | — |
Cash Flow
Financial performance
Net change in cash
| (USD) | Mar 2022info | Y/Y change |
|---|---|---|
Net income | -74.20M | -15.42% |
Cash from operations | -77.80M | -27.52% |
Cash from investing | -38.47M | -362.20% |
Cash from financing | 7.36M | 153.66% |
Net change in cash | -108.88M | -150.65% |
Free cash flow | -69.28M | -41.76% |
About
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia
Founded
1986
Headquarters
Website
Employees
358
